The Akt/mammalian target of rapamycin pathway is activated and associated with adverse prognosis in soft tissue leiomyosarcomas.
about
Activation of the Akt-mTOR pathway and receptor tyrosine kinase in patients with solitary fibrous tumors.Hypoxia-inducible factor 1 alpha is a poor prognostic factor and potential therapeutic target in malignant peripheral nerve sheath tumor.Epidemiology and therapies for metastatic sarcomaMLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma.A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas.Targeted therapy in sarcomas other than GIST tumorsAn immunohistochemical analysis of stathmin 1 expression in uterine smooth muscle tumors: differential expression in leiomyosarcomas and leiomyomas.Diverse involvement of isoforms and gene aberrations of Akt in human lung carcinomas.Elevated expression of HSP90 and the antitumor effect of an HSP90 inhibitor via inactivation of the Akt/mTOR pathway in undifferentiated pleomorphic sarcoma.Dual targeting of mTOR and aurora-A kinase for the treatment of uterine Leiomyosarcoma.Potential Therapeutic Targets in Uterine Sarcomas.Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit.Cancer-testis antigens PRAME and NY-ESO-1 correlate with tumour grade and poor prognosis in myxoid liposarcoma.Prognostic significance of MTOR pathway component expression in neuroendocrine tumors.Clinicopathological features of primary leiomyosarcoma of the gastrointestinal tract following recognition of gastrointestinal stromal tumours.Pharmacological treatment for uterine leiomyosarcomas.Activation of the Akt-mTOR and MAPK pathways in dedifferentiated liposarcomas.Association between high expression of phosphorylated Akt and mammalian target of rapamycin and improved survival in salivary gland adenoid cystic carcinoma.Effect of AKT inhibition on epithelial-mesenchymal transition and ZEB1-potentiated radiotherapy in nasopharyngeal carcinoma.Prognostic impact of the activation status of the Akt/mTOR pathway in synovial sarcoma.Meta-analysis of the prognostic value of p-4EBP1 in human malignancies.Soft tissue sarcomas: From a morphological to a molecular biological approach.Molecular biomarkers for uterine leiomyosarcoma and endometrial stromal sarcoma.RAS/MAPK pathway hyperactivation determines poor prognosis in undifferentiated pleomorphic sarcomas.Emerging targets in sarcoma: Rising to the challenge of RAS signaling in undifferentiated pleomorphic sarcoma.Phosphorylation of signal transducer and activator of transcription 3 in soft tissue leiomyosarcoma is associated with a better prognosis.Non-canonical WNT6/WNT10A signal factor expression in EBV+ post-transplant smooth muscle tumors.Antitumor profile of the PI3K inhibitor ZSTK474 in human sarcoma cell lines
P2860
Q33412198-F201D185-3A19-40A0-A1B5-32F5E3E15C31Q33739269-A676E716-2698-4EDF-BB1B-83B139D48ECFQ34652142-F399991A-979D-4C50-B0D9-540F8AA1B36EQ35096201-9A2A803A-382F-4C77-8DD8-1329C3631ADDQ35603657-BD3103F4-F9A6-4DA4-B27C-1986C898C248Q35622367-C14B0391-C541-4C0A-94E3-E1F111C97411Q35632172-012B1595-2128-4730-A278-17210E33A5E0Q35754270-63E42DC3-979D-4A37-88C6-2125AB6AA7CCQ35821721-AEC105A1-8C2A-49D5-93EC-98BF55F79FFEQ36205257-C4C5BE70-CA16-416F-ABDC-5D5967D190ACQ36245677-E287964D-084A-4AAE-8B35-51DFC7C7391FQ36514782-81569315-C09E-4E4B-A6E4-64A16F0DA6EDQ37082518-968388D7-60A4-447B-BEC3-2E19EAB35F11Q37165103-5C786649-2E12-4A25-9E22-8582E97E61E5Q38114127-4224A90E-4B0F-4D11-896C-9225D1D9CA2AQ38270671-6E5E02A8-4B53-4115-A39F-E1F829D1453CQ38823442-7B7B45D7-EADF-4338-911A-CF4ECA722EC3Q38946083-2D0C15D6-8EA9-40C1-A3AA-DE13201A9733Q42927132-8CA4CD8E-FBAF-42C2-A99C-7FFB01476A1EQ47994466-49EF2678-5510-4D22-8544-4550210C8F09Q49515435-A1DE988C-8065-453B-BC5A-EBF4B0FF0120Q51817033-EE9ABBA6-07DE-4A5D-8F6F-ADF1B5A14A14Q52320253-2CAA3A5F-C1E2-4D37-B118-AB4ED5FA63D7Q53478339-EE7B8E55-4A12-4A25-8A9E-E5491A20016AQ54239575-6BD25991-1944-4CF8-AB0D-25194A6225F9Q54508147-6BC49AB5-7636-45E7-8BCA-ABF5FEEABFDDQ55286123-4183F3F0-C4AD-4F5E-8366-AEAFAF304D86Q58738703-FEB8A125-D505-43E7-8589-747A144ABBA3
P2860
The Akt/mammalian target of rapamycin pathway is activated and associated with adverse prognosis in soft tissue leiomyosarcomas.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
The Akt/mammalian target of ra ...... n soft tissue leiomyosarcomas.
@en
The Akt/mammalian target of ra ...... n soft tissue leiomyosarcomas.
@nl
type
label
The Akt/mammalian target of ra ...... n soft tissue leiomyosarcomas.
@en
The Akt/mammalian target of ra ...... n soft tissue leiomyosarcomas.
@nl
prefLabel
The Akt/mammalian target of ra ...... n soft tissue leiomyosarcomas.
@en
The Akt/mammalian target of ra ...... n soft tissue leiomyosarcomas.
@nl
P2093
P2860
P356
P1433
P1476
The Akt/mammalian target of ra ...... in soft tissue leiomyosarcomas
@en
P2093
Hidetaka Yamamoto
Kenichi Kohashi
Kenichi Nishiyama
Nokitaka Setsu
Ryohei Yokoyama
Yoh Dobashi
Yoshinao Oda
Yukihide Iwamoto
P2860
P304
P356
10.1002/CNCR.26448
P407
P577
2011-08-11T00:00:00Z